CCL2 and posterior cortical atrophy: Thus, our mechanistic observations may explain the recent failure of CCL2 directed monoclonal therapy in PCa [49] since these trials were performed using anti-CCL2 as a single agent and in post-ADT patients who had already developed metastatic CRPC.